tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ami Fadia, 490 are a BUY (89.74%), 51 are a HOLD (9.34%), 5 are a SELL (0.92%).
Analyst Ami Fadia, currently employed at NEEDHAM, carries an average stock price target met ratio of 52.03% that have a potential upside of 39.99% achieved within 177 days.
Ami Fadia’s has documented 1,037 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 31-Jul-2026.
Analyst best performing recommendations are on PRAX (PRAXIS PRECISION MEDICINES ).
The best stock recommendation documented was for RVMD (REVOLUTION MEDICINES) at 10/12/2023. The price target of $34 was fulfilled within 4 days with a profit of $9.8 (40.5%) receiving and performance score of 101.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 19-Oct-2022
$12
$-2.26 (-15.85%)
$800
Buy Since 25-Oct-2023
$20
$5.52 (38.12%)
Hold Since 19-Jul-2023
$25
$10.52 (72.65%)
Which stock is Ami Fadia is most bullish on?
Which stock is Ami Fadia is most reserved on?
What Year was the first public recommendation made by Ami Fadia?
